These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10955913)

  • 1. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
    Neuhaus TJ; Goetschel P; Schmugge M; Leumann E
    Pediatr Nephrol; 2000 Aug; 14(8-9):713-6. PubMed ID: 10955913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
    Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
    Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
    Castelino RL; Maddula M; Tarafdar S; Sud K; Kairaitis L
    Thromb Res; 2019 Aug; 180():70-73. PubMed ID: 31229923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated premature hemofilter clotting during regional citrate anticoagulation as indicator of heparin induced thrombocytopenia.
    Lehner GF; Schöpf M; Harler U; Pechlaner C; Joannidis M
    Blood Purif; 2014; 38(2):127-30. PubMed ID: 25412655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin-associated platelet aggregation syndrome with skin necrosis during hemodialysis].
    Bredlich RO; Stracke S; Gall H; Proebstle TM
    Dtsch Med Wochenschr; 1997 Mar; 122(11):328-32. PubMed ID: 9102281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G; Minet V; Mullier F; Michaux I
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-induced thrombocytopenia in hemodialysis patients.
    Brouwer DJ; Peterson P
    Nephrol Nurs J; 2000 Apr; 27(2):240-1, 213. PubMed ID: 11111553
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
    Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M
    Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
    Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
    Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
    Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.